podcasts Ratings /ratings/en/research-insights/podcasts/2020-08-05-the-sp-pharma-dose-episode-35-regeneron-pharmaceuticals-steady-growth-vs-heavy-product-concentration content esgSubNav
In This List

The S&P Pharma Dose - Episode 35 - Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

COMMENTS

A Sudden Correction To Fast-Rising U.S. Home Prices Isn't Likely

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

RESUPD

Research Update: Australian Postal Corp. Outlook Revised To Stable On Strong Parcel Earnings; 'A+/A-1' Ratings Affirmed

What's It Worth? The Rise Of Electric Vehicles In European Auto ABS

Listen: The S&P Pharma Dose - Episode 35 - Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.